Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769274 · ClinicalTrials.gov registry record · Phase 2
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
A Phase 2 study of Inherited Erythromelalgia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT01769274 is a Phase 2 study of Inherited Erythromelalgia that has completed, run by Pfizer. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01769274, a Phase 2 study of Inherited Erythromelalgia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy and safety of single doses of PF-05089771 against placebo in treatment of pain in patients with primary, inherited erythromelalgia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-05089771
Study Locations (1)
Connecticut
- New Haven Clinical Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-10-22 |
| Est. Completion | 2013-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01769274
The ClinicalTrials.gov registry entry for NCT01769274 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inherited Erythromelalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01769274 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01769274 about?
NCT01769274 is a clinical study titled "Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia". The purpose of this study is to evaluate the efficacy and safety of single doses of PF-05089771 against placebo in treatment of pain in patients with primary, inherited erythromelalgia.
What is the current status of trial NCT01769274?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-10-22. Estimated completion is 2013-07-12.
What conditions does trial NCT01769274 study?
This clinical trial studies the following conditions: Inherited Erythromelalgia.
What interventions are being tested in trial NCT01769274?
The interventions under investigation include: Placebo (DRUG), PF-05089771 (DRUG).
Who is sponsoring clinical trial NCT01769274?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01769274 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.